Reviews
1 August 1992

Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy: A Review of the Literature and Pathophysiology

Publication: Annals of Internal Medicine
Volume 117, Number 3

Abstract

Objective: To review available information on cough and angioneurotic edema associated with angiotensin-converting enzyme (ACE) inhibitors.
Data Sources: All relevant articles from 1966 through 1991 were identified mainly through MEDLINE search and article bibliographies.
Study Selection: More than 400 articles were identified; 200 reporting incidence or possible mechanisms for the side effects or both were selected.
Data Extraction and Synthesis: All pertinent information, including incidence and mechanisms of ACE inhibitor-induced cough and angioedema, was reviewed and collated.
Conclusions: Cough occurs in 5% to 20% of patients treated with ACE inhibitors, recurring with reintroduction of the same or another ACE inhibitor. It is more common in women. The mechanism may involve accumulation of prostaglandins, kinins (such as bradykinin), or substance P (neurotransmitter present in respiratory tract C-fibers); both bradykinin and substance P are degraded by ACE.
A 4-day trial of withdrawal of the ACE inhibitor or temporary substitution of another class of antihypertensive agent inexpensively and easily ascertains if the ACE inhibitor caused the cough. Change to another ACE inhibitor or additive therapy with nonsteroidal anti-inflammatory drugs is not recommended. Prompt recognition of ACE inhibitor-related cough can prevent unnecessary diagnostic testing and treatment.
Angioedema occurs in 0.1% to 0.2% of patients receiving ACE inhibitors. The onset usually occurs within hours or, at most, 1 week after starting therapy. The mechanism may involve autoantibodies, bradykinin, or complement-system components. Treatment involves first protecting the airway, followed by epinephrine, antihistamines, and corticosteroids if needed. Therapy is then resumed with an alternate class of antihypertensive agent.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Furberg C and Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure [Editorial]. Am J Cardiol. 1985;55:1110-3.
2.
. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35.
3.
Dzau V and Creager M. Influence of angiotensin-converting enzyme inhibitors on clinical outcome and survival in congestive heart failure. Pract Cardiol. 1987;13:40-9.
4.
Newman TMaskin CDennick LMeyer JHallows B, and Cooper W. Effects of Captopril on survival in patients with heart failure. Am J Med. 1988;84(Suppl 3A):140-4.
5.
Dzau V and Creager M. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. Cardiol Clin. 1989;7:119-30.
6.
Rush J and Merrill D. The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol. 1987;9(Suppl 3):S99-S107.
7.
Davies RIrvin JKramsch DWalker J, and Moncloa F. Enalapril worldwide experience. Am J Med. 1984;77(Suppl 2A):23-35.
8.
Frolich ECooper R, and Lewis E. Review of the overall experience of Captopril in hypertension. Arch Intern Med. 1984;144:1441-4.
9.
McFate Smith WKulaga SMoncloa FPingeon R, and Walker J. Overall tolerance and safety of enalapril. J Hypertens. 1984;2(Suppl 5):S113-7.
10.
. Low-dose Captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med. 1984;144:1947-53.
11.
Edwards C and Padfield P. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet. 1985;1:30-4.
12.
Jenkins ADreslinski GTadros SGroel JFand R, and Herczog S. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol. 1985;7(Suppl 1):S96-101.
13.
DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Med Toxicol. 1986;1:122-41.
14.
Irvin J and Viau J. Safety profiles of the angiotensin converting enzyme inhibitors Captopril and enalapril. Am J Med. 1986;81(Suppl 4C):46-50.
15.
Todd P and Heel R. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986;31:198-248.
16.
Weber M and Zusman R. Converting enzyme inhibitors in the treatment of essential hypertension. Drug Ther. 1986;16:43-54.
17.
Bolzano KArriaga JBernal RBernantes HCalderon J, and Debruyn J. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 1987;9(Suppl 3):S43-7.
18.
Armayor G and Lopez L. Lisinopril: a new angiotensin-converting enzyme inhibitor. Drug Intell Clin Pharm. 1988;22:365-72.
19.
Brogden RTodd P, and Sorkin E. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988;36:540-600.
20.
Gavras H. A multicenter trial of enalapril in the treatment of essential hypertension. Clin Ther. 1986;9:24-38.
21.
Inman WRawson NWilton LPearce G, and Speirs C. Post-marketing surveillance of enalapril. I: Results of prescription-event monitoring. BMJ. 1988;297:826-9.
22.
Kostis J. Angiotensin converting enzyme inhibitors. II. Clinical use. Am Heart J. 1988;116:1591-605.
23.
Rumboldt ZMarinkovic M, and Drinovec J. Enalapril versus Captopril: a double-blind multicentre comparison in essential hypertension. Int J Clin Pharmacol Res. 1988;8:181-8.
24.
Warner N and Rush J. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs. 1988;35(Suppl 5):89-97.
25.
Weber M. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med. 1988;84(Suppl 4A):16-23.
26.
Arr SWoollard MFairhurst GPippen CRao S, and Cooper W. Safety and efficacy of enalapril in essential hypertension in the elderly. Br J Clin Pharmacol. 1985;20:279P-80P.
27.
Jenkins AKnill J, and Dreslinski G. Captopril in the treatment of the elderly hypertensive patient. Arch Intern Med. 1985; 145:2029-31.
28.
Creisson CBaulac L, and Lenfant B. Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study. Postgrad Med J. 1986;62(Suppl 1):139-41.
29.
Murphy PVan dCammen T, and Malone-Lee J. Captopril in elderly patients with heart failure. Br Med J (Clin Res Ed). 1986; 293:239-40.
30.
Laher MNatin DRao SJones R, and Carr P. Lisinopril in elderly patients with hypertension. J Cardiovasc Pharmacol. 1987;9(Suppl 3):S69-71.
31.
Reid J. Angiotensin converting enzyme inhibitors in the elderly. Br Med J. 1987;295:943-4.
32.
Cox JDuggan JO'Boyle CMee FWalsh J, and Coakley D. A double-blind evaluation of Captopril in elderly hypertensives. J Hypertens. 1989;7:299-303.
33.
Cooper WSheldon DBrown DKimber GIsitt V, and Currie W. Post-marketing surveillance of enalapril: experience in 11, 710 hypertensive patients in general practice. J R Coll Gen Pract. 1987;37:346-9.
34.
Nicholls M. Side effects and metabolic effects of converting-enzyme inhibitors. Clin Exp Hypertens. 1987;A9(2-3):653-64.
35.
Omae TKawano Y, and Yoshida K. Side effects and metabolic effects of converting enzyme inhibitors. Clin Exp Hypertens. 1987;A9(2-3):635-42.
36.
Havelka JBoerlin HStuder AGreminger PTenschert W, and Luescher T. Long-term experience with Captopril in severe hypertension. Br J Clin Pharmacol. 1982;14(Suppl 2):71S-76S.
37.
Knoben J. [Tickling cough due to Captopril] [Letter]. Ned Tijdschr Geneeskd. 1983;127:1306.
38.
Leier CBambach DNelson SHermiller JHuss P, and Magorien R. Captopril in primary pulmonary hypertension. Circulation. 1983;67:155-61.
39.
Richardson DBane BProctor JRaper J, and Wasserman A. Enalapril in the treatment of moderate hypertension [Abstract 735]. Presented at the 10th Scientific Meeting of the International Society of Hypertension, Interlaken, Switzerland, 1984.
40.
Sesoko S and Kaneko Y. Cough associated with the use of Captopril [Letter]. Arch Intern Med. 1985; 145:1524.
41.
Inman W. Enalapril-induced cough [Letter]. Lancet. 1986;2:1218.
42.
Mitchell AGillies ACarney S, and Smith A. Cough and Captopril [Letter]. Arch Intern Med. 1986;146:1017.
43.
Nash D. Lisinopril cough [Letter]. Postgrad Med. 1986;80:40, 46.
44.
Rossetto B. Side effect of Captopril and enalapril [Letter]. West J Med. 1987;146:102.
45.
Semple P and Herd G. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme [Letter]. N Engl J Med. 1986;314:61.
46.
Stark R. Mechanism of cough with angiotensin-converting enzyme inhibition [Letter]. Arch Intern Med. 1986;146:1227.
47.
Webb DBenjamin NCollier J, and Robinson B. Enalapril-induced cough [Letter]. Lancet. 1986;2:1094.
48.
Enalapril as first choice treatment of mild, moderate and severe essential hypertension: results of an open multicentre clinical trial: New Zealand Hypertension Study Group. N Z Med J. 1987;100:137-9.
49.
Benchimol HAouizerate EGosse PVergeret JCourty G, and Granger Veyron B. [Cough induced by converting enzyme inhibitors. 15 cases] [Letter]. Presse Med. 1987;16:1432-3.
50.
Chalmers DDombey S, and Lawson D. Post marketing surveillance of Captopril (for hypertension): a preliminary report. Br J Clin Pharmacol. 1987;24:343-9.
51.
Coulter D and Edwards I. Cough associated with Captopril and enalapril. Br Med J (Clin Res Ed). 1987;294:1521-3.
52.
Doering WMaass LIrmisch R, and Konig E. Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. Am J Cardiol. 1987;59:60D-64D.
53.
Fuller R and Choudry N. Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. Br Med J (Clin Res Ed). 1987;295:1025-6.
54.
Fyhrquist FGronhagen-Riska CTikkanen I, and Junggren I. Longterm monotherapy with lisinopril in renovascular hypertension. J Cardiovasc Pharmacol. 1987;9(Suppl 3):S61-5.
55.
Hood SNicholls M, and Gilchrist N. Cough with angiotensin converting-enzyme inhibitors. N Z Med J. 1987;100:6-7.
56.
Irwin RRosen M, and Braman S. Cough. A comprehensive review. Arch Intern Med. 1977;137:1186-91.
57.
McNally E. Cough due to Captopril. West J Med. 1987;146:226-8.
58.
Morice ALowry RBrown M, and Higenbottam T. Angiotensin-converting enzyme and the cough reflex. Lancet. 1987;2:1116-8.
59.
Ollivier JDucrocq M, and Droniou J. [A secondary effect of converting enzyme inhibitors: cough]. Presse Med. 1987;16:759-61.
60.
Predel HDusing RBacker AKipnowski J, and Kramer H. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. Am J Cardiol. 1987;59:143D-148D.
61.
Town GHallwright GMaling T, and O'Donnell T. Angiotensin converting enzyme inhibitors and cough. N Z Med J. 1987;100:161-3.
62.
Tugwell S and Stokes G. Angiotensin converting-enzyme inhibitor agents and respiratory symptoms [Letter]. Med J Aust. 1987;147:263-4.
63.
Umeki S. Angiotensin-converting enzyme inhibitors and cough [Letter]. Lancet. 1987;2:1526.
64.
Bucknall CNeilly JCarter RStevenson R, and Semple P. Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed). 1988;296:86-8.
65.
Goldszer RLilly L, and Solomon H. Prevalence of cough during angiotensin-converting enzyme inhibitor therapy [Letter]. Am J Med. 1988;85:887.
66.
Lenhardt E and Ziegler M. Cough caused by Cilazapril. Am J Med Sci. 1988;296:119-20.
67.
Stokes GTugwell SO'Neill MHunyor S, and Pigott P. A.C.E. inhibitors and cough. Aust Fam Physician. 1988;17:275-6.
68.
Thysell HAndersson KAndersson S, and Eckman R. Angiotensin-converting enzyme inhibition, cough and the serum concentration of substance P. Eur J Clin Pharmacol. 1988;34:649-50.
69.
Berkin K. Respiratory effects of angiotensin converting enzyme inhibition. Eur Respir J. 1989;2:198-201.
70.
Boulet LMilot JLampron N, and Lacourciere Y. Pulmonary function and airway responsiveness during long-term therapy with Captopril. JAMA. 1989;261:413-6.
71.
Gibson G. Enalapril-induced cough. Arch Intern Med. 1989;149:2701-3.
72.
Hume AMurphy J, and Lauerman S. Angiotensin-converting enzyme inhibitor-induced cough. Pharmacotherapy. 1989;9:88-90.
73.
Kaufman JCasanova JRiendl P, and Schleuter D. Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest. 1989;95:544-8.
74.
McEwan JChoudry NStreet R, and Fuller R. Change in cough reflex after treatment with enalapril and ramipril. BMJ. 1989;299:13-6.
75.
Morice ABrown M, and Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol. 1989;13(Suppl 3):S59-S62.
76.
Puolijoki HNieminen MMoilanen ESiitonen LLahdensuo A, and Reinikainen P. Cough induced by enalapril but not by Captopril. Eur Respir J. 1989;2:289-91.
77.
Strocchi EValtancoli G, and Ambrosioni E. The incidence of cough during treatment with angiotensin converting enzyme inhibitors. J Hypertens. 1989;7(Suppl 6):S308-9.
78.
Warner NRush J, and Keegan M. Tolerability of enalapril in congestive heart failure. Am J Cardiol. 1989;63:33D-37D.
79.
Whalen JSkalky CDeSilva J, and Weber M. Peak and trough effects of 3 once daily dose levels of benazepril in mild-moderate hypertension [Abstract]. Am J Hypertens. 1989;2:45A.
80.
Brown C. The safety and acceptability of Perindopril. J Hum Hypertens. 1990;4(Suppl 4):51-5.
81.
Poole M and Postma D. Characterization of cough associated with angiotensin-converting enzyme inhibitors. Otolaryngol Head Neck Surg. 1991;105:714-6.
82.
Canessa P and Torraca A. [Bronchial reactivity and cough due to ACE inhibitors]. Medicina (Firenze). 1990;10:296-8.
83.
Hakas J. Topical capsaicin induces cough in patients receiving ACE inhibitor [Letter]. Ann Allergy. 1990;65:322-3.
84.
Le Menn G. [The French ambulatory multicenter trial of Triatec: conclusions of the trial]. Rev Prat. 1990;40(Suppl 18):48-50.
85.
Schnaper H. Use of quinapril in the elderly patient. Am J Hypertens. 1990;3:278S-282S.
86.
Ogihara TKaneko YIkeda MYamada KOmae T, and Arakawa K. Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril. Am J Hypertens. 1991;4:42S-45S.
87.
Saruta T and Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hypertens. 1991;4:23S-28S.
88.
Sebastian JMcKinney WKaufman J, and Young M. Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest. 1991;99:36-9.
89.
Capella DTorres FAvila PMoreno V, and Laporte J. [Cough caused by angiotensin-converting enzyme inhibitors. A series of cases collected by spontaneous notification of adverse reactions.] Med Clin (Barc). 1991;96:126-8.
90.
Lacourciere YPoirier LProvencher P, and Guivarch P. Once vs twice daily administration of a fixed combination of Captopril plus hydrochlorothiazide in essential hypertension: a double-blind crossover study in known responders to a standard combination. Br J Clin Pharmacol. 1991;32:115-9.
91.
Richardson P and Peatfield A. Reflexes concerned in the defence of the lungs. Bull Eur Physiopathol Respir. 1981;17:979-1012.
92.
McCool F and Leith D. Pathophysiology of cough. Clin Chest Med. 1987;8:189-95.
93.
Higenbottam T. The ionic composition of airway surface liquid and coughing. Bull Eur Physiopathol Respir. 1987;23(Suppl 10):25S-27S.
94.
Bertoli LFusco MLo Cicero SMicallef E, and Busnardo I. Influence of ACE inhibition on pulmonary haemodynamics and function in patients in whom beta-blockers are contraindicated. Postgrad Med J. 1986;62(Suppl 1):47-51.
95.
Lindgren B and Andersson R. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med Toxicol Adverse Drug Exp. 1989;4:369-80.
96.
Skidgel R and Erdos E. Cleavage of peptide bonds by angiotensin I converting enzyme. Agents Actions. 1987;22(Suppl):289-96.
97.
Cascieri MBull HMumford RPatchett AThornberry N, and Liang T. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by Captopril and MK-422. Mol Pharmacol. 1984;25:287-93.
98.
Kaufman MColeridge HColeridge J, and Baker D. Bradykinin stimulates afferent vagal C-fibers in intrapulmonary airways of dogs. J Appl Physiol. 1980;48:511-7.
99.
Newball H and Keiser H. Relative effects of bradykinin and histamine on the respiratory system of man. J Appl Physiol. 1973;35:552-6.
100.
Fuller RDixon CCuss F, and Barnes P. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis. 1987;135:176-80.
101.
Varonier H and Panzani R. The effect of inhalations of bradykinin on healthy and atopic (asthmatic) children. Int Arch Allergy Immunol. 1968;34:293-6.
102.
Greenberg ROsman GO'Keefe E, and Antonaccio M. The effects of Captopril (SQ 14,225) on bradykinin-induced broncho-constriction in the anaesthetised guinea pig. Eur J Pharmacol. 1979;57:287-94.
103.
Ferner RSimpson J, and Rawlins M. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed). 1987;294:1119-20.
104.
Fuller RWarren JMcCusker M, and Dollery C. Effect of enalapril on the skin response to bradykinin in man. Br J Clin Pharmacol. 1987;23:88-90.
105.
Anderson M and deShazo R. Studies of the mechanism of angioten-sin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J Allergy Clin Immunol. 1990;85:856-8.
106.
Swartz S and Williams G. Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol. 1982;49:1405-9.
107.
Liu MBleecker ENiv YKadey-Sobotka AMcLemore T, and Purmutt S. Asthma is characterized by elevated levels of bronchospastic prostaglandins and histamine in airway fluids obtained by bronchoalveolar lavage [Abstract]. FASEB J. 1988;2:A1698.
108.
Goetzl E. Asthma: new mediators and old problems [Editorial]. N Engl J Med. 1984;311:252-3.
109.
Rossoni GOmini CVigano TMandelli VFolco G, and Berti F. Bronchoconstriction by histamine and bradykinin in guinea pigs: relationship to thromboxane A2 generation and the effect of aspirin. Prostaglandins. 1980;20:547-57.
110.
Johnston CYasujima M, and Clappison B. The kallikrein-kinin system and angiotensin converting enzyme inhibition in hypertension. In: Horovitz ZP; ed. Angiotensin Converting Enzyme Inhibitors. Mechanisms of Action and Clinical Implications. Baltimore: Urban & Schwarzenberg; 1981:123-39.
111.
Johnston CClappison BAnderson W, and Yasujima M. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol. 1982;49:1401-4.
112.
Regoli D and Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
113.
Dixon CFuller R, and Barnes P. The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial response to inhaled histamine and bradykinin in asthmatic subjects. Br J Clin Pharmacol. 1987;23:91-3.
114.
Rodriguez FGil Vdel Carmen Beneyto M, and Lopez-Vidriero E. Effects of Captopril once daily on blood pressure and angiotensin converting enzyme in hypertensive patients. Postgrad Med J. 1986;62(Suppl 1):94-6.
115.
Larochelle PGenest JKuchel OBoucher RGutkowska Y, and McKinstry D. Effect of Captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity. Can Med Assoc J. 1979;121:309-16.
116.
Unger TSchull BHubner DYukimora TLang R, and Rascher W. Plasma-converting enzyme activity does not reflect effectiveness of oral treatment with Captopril. Eur J Pharmacol. 1981;72:255-9.
117.
Fyhrquist FGronhagen-Riska CHortung LForslund TTikkanen I, and Klockars M. The induction of angiotensin converting enzyme by its inhibitors. Clin Exp Hypertens. 1983;A5:1319-30.
118.
Ulm E and Vassil T. Total serum angiotensin converting activity in rats and dogs after enalapril maleate (MK-421). Life Sci. 1982;30:1225-30.
119.
Stanziola LGreene L, and Santos R. Effect of long-term angiotensin converting enzyme inhibition on bradykinin metabolism in conscious rats [Abstract]. Hypertension. 1989;13:516-7.
120.
Umeki SOhga ROno SYasuda TMorimoto K, and Terao A. Angiotensin I level and sporadic hypokalemic periodic paralysis. Arch Intern Med. 1986;146:1956-60.
121.
Umeki STerao A, and Sawayama T. A new syndrome: angiotensin-converting enzyme dysfunction syndrome: differential diagnosis and pathogenesis—case reports. Angiology. 1988;39:58-67.
122.
Hinojosa MQuirce SPuyana JCodina J, and Garcia-Rull S. Bronchial hyperreactivity and cough induced by angiotensin-converting enzyme-inhibitor therapy [Letter]. J Allergy Clin Immunol. 1990; 85:818-9.
123.
Lindgren BRosenqvist UEkstrom TGronneberg RKarlberg B, and Andersson R. Increased bronchial reactivity and potentiated skin responses in hypertensive subjects suffering from cough during ACE-inhibitor therapy. Chest. 1989;95:1225-30.
124.
Collier J and Fuller R. Capsaicin inhalation in man and the effects of sodium cromoglycate. Br J Pharmacol. 1984;81:113-7.
125.
Ogihara TMikami HKatahira K, and Otsuka A. Comparative study of the effects of three angiotensin converting enzyme inhibitors on the cough reflex. Am J Hypertens. 1991;4:46S-51S.
126.
Kaufman JCasanova JRiendl P, and Schlueter D. Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest. 1989;95:544-8.
127.
Sala HAbad JJuanmiquel LPlans CRuiz J, and Roig J. Captopril and bronchial reactivity. Postgrad Med J. 1986;62(Suppl 1):76-7.
128.
Sant'Ambrogio G. Afferent pathways for the cough reflex. Bull Eur Physiopathol Respir. 1987;23(Suppl 10):19S-23S.
129.
Fuller RDixon C, and Barnes P. Bronchoconstrictor response to inhaled capsaicin in humans. J Appl Physiol. 1985;58:1080-4.
130.
Winning AHamilton RShea S, and Guz A. Respiratory and cardiovascular effects of central and peripheral intravenous injections of capsaicin in man: evidence for pulmonary chemosensitivity. Clin Sci. 1986;71:519-26.
131.
Buck S and Burks T. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev. 1986;38:179-226.
132.
Kellstein DPrice DHayes R, and Mayer D. Evidence that substance P selectively modulates C-fiber-evoked dicharges of dorsal horn nociceptive neurons. Brain Res. 1990;526:291-8.
133.
Joos GPauwels R, and van der Straeten M. Effect of inhaled substance P and neurokinin A on the airways of normal and asthmatic subjects. Thorax. 1987;42:779-83.
134.
Barnes P. Neuropeptides in human airways: function and clinical implications. Am Rev Respir Dis. 1987;136:S77-S83.
135.
Lundberg JMartling C, and Saria A. Substance P and capsaicin-induced contraction of human bronchi. Acta Physiol Scand. 1983; 119:49-53.
136.
Shore SStimler-Gerard NCoats S, and Drazen J. Substance P-induced bronchoconstriction in the guinea pig. Enhancement by inhibitors of neutral metalloendopeptidase and angiotensin-converting enzyme. Am Rev Resp Dis. 1988;137:331-6.
137.
Coleridge HColeridge JGinzel KBaker GBanzett R, and Morrison M. Stimulation of 'irritant' receptors and afferent C-fibres in the lungs by prostaglandins. Nature. 1976;264:451-3.
138.
Gilchrist NRichards AMarch M, and Nicholls M. Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study. J Hum Hypertens. 1989;3:451-5.
139.
Le Jeunne CBiour MLowenstein WHugues F, and Cheymol G. [Cough provoked by angiotensin-converting enzyme inhibitors. Effect of non-steroidal anti-inflammatory agents]. Rev Mal Respir. 1988;5:645-7.
140.
Biour MLe Jeunne CHugues F, and Cheymol G. [Diclofenac and cough induced by converting enzyme inhibitors] [Letter]. Therapie. 1988;43:122-3.
141.
McEwan JChoudry N, and Fuller R. The effect of sulindac on the abnormal cough reflex associated with dry cough. J Pharmacol Exp Ther. 1990;255:161-4.
142.
Hartung HHeininger KSchafer B, and Toyka K. Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism. FASEB J. 1988;2:48-51.
143.
Yeo WRamsay L, and Morice A. ACE inhibitor cough: a genetic link? [Letter]. Lancet. 1991;337:187.
144.
Fujimura MSakamoto SKamio Y, and Matsuda T. Sex difference in the inhaled tartaric acid cough threshold in non-atopic healthy subjects. Thorax. 1990;45:633-4.
145.
Fujita TYamashita N, and Yamashita K. Effect of indomethacin on antihypertensive action of Captopril in hypertensive patients. Clin Exp Hypertens. 1981;3:939-52.
146.
Koopmans Pvan Megen TThien T, and Gribnau F. The interaction between indomethacin and Captopril or enalapril in healthy volunteers. J Intern Med. 1989;226:139-42.
147.
Champion R. Urticaria. In: Rook A, Wilkinson DS, Ebling FJ; eds. Textbook of Dermatology. London: Blackwell; 1979:971-9.
148.
Wilkin JHammond J, and Kirkendall W. The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol. 1980;116:902-5.
149.
Abrams WDavies R, and Ferguson R. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. Fed Proc. 1984;43:1314-21.
150.
Goodfield M and Millard L. Severe cutaneous reactions to Captopril. Br Med J (Clin Res Ed). 1985;290:1111.
151.
Kallenberg C. Severe cutaneous reaction to Captopril [Letter]. Br Med J. 1985;290:1829.
152.
Furness PGoodfield MMacLennan KStevens A, and Millard L. Severe cutaneous reactions to Captopril and enalapril: histological study and comparison with early mycosis fungoides. J Clin Pathol. 1986;39:902-7.
153.
Singer D and MacGregor G. Angioneurotic oedema associated with two angiotensin converting enzyme inhibitors [Letter]. Br Med J. 1986;293:1243.
154.
Seidman MLewansowski CSarpa JPotesta E, and Schweitzer V. Angioedema related to angiotensin-converting enzyme inhibitors. Otolaryngol Head Neck Surg. 1990;102:727-31.
155.
Suarez MHo PJohnson E, and Perez G. Angioneurotic edema, agranulocytosis, and fatal septicemia following Captopril therapy. Am J Med. 1986;81:336-8.
156.
Wood SMann R, and Rawlins M. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed). 1987;294:91-2.
157.
Roberts J and Wuerz R. Clinical characteristics of angiotensinconverting enzyme inhibitor-induced angioedema. Ann Emerg Med. 1991;20:555-8.
158.
Donohoe JKelly JLaher M, and Doyle G. Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med. 1988;85(Suppl 3B):31-4.
159.
Wernze H. [Angioneurotic edema caused by angiotensin-converting enzyme inhibitors: incidence, clinical characteristics, mechanisms of action]. Z Kardiol. 1988;77(Suppl 3):61-4.
160.
Slater EMerrill DGuess HRoylance PCooper W, and Inman W. Clinical profile of angioedema associated with angiotensin converting enzyme inhibition. JAMA. 1988;260:967-70.
161.
Barna J and Frable M. Life-threatening angioedema. Otolaryngol Head Neck Surg. 1990;103:795-8.
162.
Cameron H and Higgins T. Clinical experience with lisinopril. Observations on safety and tolerability. J Hum Hypertens. 1989;3:177-86.
163.
Cameron D. Near fatal angioedema associated with Captopril. Can J Cardiol. 1990;6:265-6.
164.
Chin H and Buchan D. Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor [Letter]. Ann Intern Med. 1990;112:312-3.
165.
Gianos MKlaustermeyer WKurohara MTarnasky P, and Gordon E. Enalapril induced angioedema. Am J Emerg Med. 1990;8:124-6.
166.
Lanting PBrouwers Tvan Buuren H, and Strieker B. [Angioedema caused by enalapril]. Ned Tijdschr Geneeskd. 1991;135:335-7.
167.
Maclean DRamsay L, and Richardson P. Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6 month comparison. Br J Clin Pharmacol. 1990;30:203-11.
168.
Shepherd G. Possible contraindication of angiotensin converting enzyme inhibitors in patients with hereditary angioedema [Letter]. Am J Med. 1990;88:446.
169.
Orfan NPatterson R, and Dykewicz M. Severe angiodema related to ACE inhibitors in patients with a history of idiopathic angioedema. JAMA. 1990;264:1287-9.
170.
Agostoni A and Cicardi M. Contraindications to the use of ACE inhibitors in patients with Cl esterase inhibitor deficiency [Letter]. Am J Med. 1991;90:278.
171.
Bi CSoltani KSloan JWeber RElliott W, and Murphy M. Tissue-specific autoantibodies induced by Captopril [Abstract]. Clin Res. 1987;35:922A.
172.
Kallenberg C. Autoantibodies during Captopril treatment [Letter]. Arthritis Rheum. 1985;28:597-8.
173.
Yeung JColeman J, and Park B. Drug-protein conjugates—IX. Immunogenecity of captopril-protein conjugates. Biochem Pharmacol. 1985;34:4005-12.
174.
Coleman JYeung JRoberts DBret ken ridge A, and Park B. Drug-specific antibodies in patients receiving Captopril. Br J Clin Pharmacol. 1986;22:161-5.
175.
Navis Gde Jong PKallenberg Cde Monchy J, and de Zeeuw D. Absence of cross-reactivity between Captopril and enalapril [Letter]. Lancet. 1984;1:1017.
176.
Gavras I and Gavras H. Captopril and enalapril [Letter]. Ann Intern Med. 1983;98:556-7.
177.
Oyvin LGaponyuk PVolodin VOyvin V, and Tokayev O. Mechanisms of blood vessel permeability derangement under the influence of permeability factors (histamine, serotonin, kinins) and inflammatory agents. Biochem Pharmacol. 1972;21:89-95.
178.
Basran GMorley JPaul W, and Turner-Warwick M. Evidence in man of synergistic interaction between putative mediators of acute inflammation and asthma. Lancet. 1982;1:935-7.
179.
Ferner RWilson DPaterson JWilkinson R, and Rawlins M. The effects pf intradermal bradykinin are potentiated by angiotensin converting enzyme inhibitors in hypertensive patients. Br J Clin Pharmacol. 1989;27:337-42.
180.
Bork KWitzke GArtmann KBenes PBockers M, and Kreuz W. Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria. Arch Dermatol Res. 1984;276:375-80.
181.
Barrow SDollery CHeavey DHickling NRitter J, and Vial J. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Clin Pharmacol. 1986;87:243-7.
182.
Auchincloss JStreeten DGilbert R, and Peppi D. Dyspnea in patients with hyperbradykininism and excessive venous pooling. Am J Med. 1986;81:260-6.
183.
Frank MGelfand J, and Atkinson J. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:580-93.
184.
Quastel MHarrison RCicardi MAlper C, and Rosen F. Behavior in vivo of normal and dysfunctional Cl inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest. 1983;71:1041-6.
185.
Frank M. Cl esterase inhibitor. Clinical clues to the pathophysiology of angioedema [Editorial]. J Allergy Clin Immunol. 1986;78:848-50.
186.
Ratnoff OPensky JOgston D, and Naff G. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C′1r subcomponent of the first component of complement by serum C′1 esterase inhibitor. J Exp Med. 1969;129:315-31.
187.
Donaldson VRatnoff ODiaz Da Silva W, and Rosen F. Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J Clin Invest. 1969;48:642-53.
188.
Gelfand JBoss GConley CReinhart R, and Frank M. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore). 1979;58:321-8.
189.
Schreiber AZweiman BAtkins PGoldwein FPietra G, and Atkinson B. Acquired angioedema with lymphoproliferative disorder: association of Cl inhibitor deficiency with cellular abnormality. Blood. 1976;48:567-80.
190.
Jackson J and Feighery C. Autoantibody-mediated acquired deficiency of C1 inhibitor [Letter]. N Engl J Med. 1988;318:122-3.
191.
Spath PWuthrich BMatter LLoos M, and Alsenz J. Acquired angioedema and anti-C1-inhibitor autoantibody [Letter]. Arch Intern Med. 1989;149:1213, 1216.
192.
Caspritz GAlpermann H, and Schleyerbach R. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Arzneimittelforschung. 1986;36:1605-8.
193.
Hentges FHumbel RDicato MHemmer R, and Kuntziger H. Acquired C1 esterase-inhibitor deficiency: case report with emphasis on complement and kallikrein activation during two patterns of clinical manifestations. J Allergy Clin Immunol. 1986;78:860-7.
194.
Lindgren BAnderson C, and Andersson R. Potentiation of inflammatory reactions in guinea-pig skin by an angiotensin converting enzyme inhibitor (MK 422). Eur J Pharmacol. 1987;135:383-7.
195.
Mathews KPan PGardner N, and Hugli T. Familial carboxypeptidase N deficiency. Ann Intern Med. 1980;93:443-5.
196.
Vaith PBender K, and Peter H. [Angioneurotic edema in hereditary alpha-1-antitrypsin deficiency]. Immun Infekt. 1991;19:27-9.

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 117Number 31 August 1992
Pages: 234 - 242

History

Published in issue: 1 August 1992
Published online: 1 December 2008

Keywords

Authors

Affiliations

Zafar H. Israili, PhD
From Emory University School of Medicine, Atlanta, Georgia. For current author addresses, see end of text.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Zafar H. Israili, W. Dallas Hall. Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy: A Review of the Literature and Pathophysiology. Ann Intern Med.1992;117:234-242. doi:10.7326/0003-4819-117-3-234

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media